Journal
BLOOD CELLS MOLECULES AND DISEASES
Volume 28, Issue 2, Pages 169-180Publisher
ACADEMIC PRESS INC ELSEVIER SCIENCE
DOI: 10.1006/bcmd.2002.0502
Keywords
erythroid differentiation; erythropoietin; glucocorticoids; estradiol; thalassemia
Categories
Funding
- NHLBI NIH HHS [HL-46557] Funding Source: Medline
- NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL146557, R01HL046557] Funding Source: NIH RePORTER
Ask authors/readers for more resources
We describe a new two-step culture method for mass production in vitro of erythroid cells from either CD34(+) (10(5) cells/mL) or light-density (10(6) cells/mL) cells purified from the blood of normal donors and thalassemic patients. The method includes (i) culture of the cells in the presence of dexamethasone and estradiol(10(-6) M each) and (ii) the growth factors SCF (50 ng/mL), IL-3 (1 ng/mL), and EPO (1 U/mL). In their proliferative phase, these cultures generated congruent to 1-2 x 10(7) erythroblasts for each milliliter of blood collected from normal donors or thalassemic patients. They were composed mostly (90%) of CD45(low)/glycophorin (GPA)(neg)/CD71(low) cells at day 7, 50 - 60% of which became CD45(neg)/GPA(+)/CD71(high) by days 15-20. However, when cells from days 7 to 12 of the proliferative phase were transferred in differentiation medium containing EPO and insulin, they progressed to mature erythroblasts (>90% benzidine(pos) and CD45(neg)/GPA(+)/CD71(medium)) in 4 days. Because of the high number of erythroid cells that are generated from modest volumes of blood, this method will prove useful in donor-specific studies of erythroid differentiation. (C) 2002 Elsevier Science (USA).
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available